IGF2BP1 and cancer

doi:10.3760/cma.j.cn371439-20200923-00017

Abstract

Abstract:

The insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a key regulator of mRNA metabolism and transport during development. Recent studies indicate that IGF2BP1 is aberrantly expressed in liver cancer, lung cancer, colon cancer, ovarion cancer, breast cancer, etc.. IGF2BP1 expression is found to promote tumor cell proliferation, migration, invasion, and correlate with poor prognosis. Further understanding of the mechanism of IGF2BP1 in malignancy may provide new targeted therapy strategies.

Key words: Neoplasms, RNA, messenger, Molecular targeted therapy, Insulin-like growth factor 2 mRNA-binding protein 1

He Zhefeng, Pei Tiemin, Meng Qinghui. IGF2BP1 and cancer[J]. Journal of International Oncology, 2021, 48(2): 92-95.

References 12

[1]	Bell JL, Wächter K, Mühleck B, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?[J]. Cell Mol Life Sci, 2013,70(15):2657-2675. DOI: 10.1007/s00018-012-1186-z. doi: 10.1007/s00018-012-1186-z
[2]	Carmel MS, Kahane N, Oberman F, et al. A novel role for VICKZ proteins in maintaining epithelial integrity during embryogenesis[J]. PLoS One, 2015,10(8):e0136408. DOI: 10.1371/journal.pone.0136408. doi: 10.1371/journal.pone.0136408
[3]	Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyla-denosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018,20(3):285-295. DOI: 10.1038/s41556-018-0045-z. doi: 10.1038/s41556-018-0045-z
[4]	Biswas J, Nunez L, Das S, et al. Zipcode binding protein 1 (ZBP1; IGF2BP1): a model for sequence-specific RNA regulation[J]. Cold Spring Harb Symp Quant Biol, 2019,84:1-10. DOI: 10.1101/sqb.2019.84.039396. doi: 10.1101/sqb.2019.84.039396 pmid: 32086331
[5]	Gutschner T, Hämmerle M, Pazaitis N, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma[J]. Hepatology, 2014,59(5):1900-1911. DOI: 10.1002/hep.26997. doi: 10.1002/hep.26997
[6]	Yuan P, Meng L, Wang N. SOX12 upregulation is associated with metastasis of hepatocellular carcinoma and increases CDK4 and IGF2BP1 expression[J]. Eur Rev Med Pharmacol Sci, 2017,21(17):3821-3826. pmid: 28975985
[7]	Peng L, Yuan XQ, Zhang CY, et al. The emergence of long non-coding RNAs in hepatocellular carcinoma: an update[J]. J Cancer, 2018,9(14):2549-2558. DOI: 10.7150/jca.24560. doi: 10.7150/jca.24560 pmid: 30026854
[8]	Xu Y, Zheng Y, Liu H, et al. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction[J]. Int J Oncol, 2017,51(3):791-800. DOI: 10.3892/ijo.2017.4066. doi: 10.3892/ijo.2017.4066 pmid: 28677801
[9]	Zhou X, Zhang CZ, Lu SX, et al. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma[J]. Oncogene, 2016,35(38):5078. DOI: 10.1038/onc.2016.61. pmid: 27477694
[10]	Jiang T, Li M, Li Q, et al. MicroRNA-98-5p inhibits cell proliferation and induces cell apoptosis in hepatocellular carcinoma via targeting IGF2BP1[J]. Oncol Res, 2017,25(7):1117-1127. DOI: 10.3727/096504016X14821952695683. doi: 10.3727/096504016X14821952695683 pmid: 28244848
[11]	Fawzy IO, Hamza MT, Hosny KA, et al. miR-1275: a single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma[J]. FEBS Lett, 2015,589(17):2257-2265. DOI: 10.1016/j.febslet.2015.06.038. doi: 10.1016/j.febslet.2015.06.038 pmid: 26160756
[12]	Rebucci M, Sermeus A, Leonard E, et al. miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1[J]. Mol Cancer, 2015,14:79. DOI: 10.1186/s12943-015-0349-6. pmid: 25889892

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.